https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39575 Wed 27 Jul 2022 14:43:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54397 Wed 21 Feb 2024 15:48:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51652 Wed 13 Sep 2023 10:00:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13691 Wed 11 Apr 2018 17:01:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28397 Wed 11 Apr 2018 15:14:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25641 Wed 11 Apr 2018 15:12:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39516 Wed 10 Aug 2022 11:31:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45667 Wed 02 Nov 2022 15:59:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34542 Tue 26 Mar 2019 15:11:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53300 Tue 21 Nov 2023 12:02:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27384 Tue 13 Oct 2020 19:16:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51433 Tue 05 Sep 2023 17:53:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51306 Thu 31 Aug 2023 14:27:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52120 Thu 28 Sep 2023 15:04:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46515 Thu 24 Nov 2022 15:50:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36736 Thu 02 Jul 2020 16:31:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20798 Sat 24 Mar 2018 08:05:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19533 95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.]]> Sat 24 Mar 2018 08:02:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20329 Sat 24 Mar 2018 07:55:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28805 P < 10⁻¹²). However, the female-to-male ratio in patients with relapse-onset multiple sclerosis and zero relapses in any given year was double that of the patients with primary progressive multiple sclerosis. Patient age was a more important determinant of decline in relapse incidence than disease duration (P < 10⁻¹²). Females are predisposed to higher relapse activity than males. However, this difference does not explain the markedly lower female-to-male sex ratio in primary progressive multiple sclerosis. Decline in relapse activity over time is more closely related to patient age than disease duration.]]> Sat 24 Mar 2018 07:38:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30262 p [signed-rank] < 0.0001), a 64% reduction in the rate of first relapse (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.28–0.47; p < 0.001), and a 27% reduction in the rate of discontinuation (HR 0.73, 95% CI 0.58–0.93; p = 0.01), compared with first-line IFN-β/GA therapy. Confirmed disability progression and area under the Expanded Disability Status Scale–time curve analyses were not significant. Similar relapse and treatment persistence results were observed in each of the higher disease activity subgroups. Conclusions: This study provides Class IV evidence that first-line natalizumab for RRMS improves relapse and treatment persistence outcomes compared to first-line IFN-β/GA. This needs to be balanced against the risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients. Classification of evidence: This study provides Class IV evidence that first-line natalizumab for RRMS improves relapse rates and treatment persistence outcomes compared to first-line IFN-β/GA.]]> Sat 24 Mar 2018 07:33:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24856 -22). On-therapy relapses carried greater burden than off-therapy relapses. Cumulative treatment exposure was independently associated with lower EDSS at 10 years (coeff=-0.86, p=1.3x10^-9). Furthermore, pregnancies were also independently associated with lower EDSS scores over the 10-year observation period (coeff=-0.36, p=0.009).We provide evidence of long-term treatment benefit in a large registry cohort, and provide evidence of long-term protective effects of pregnancy against disability accrual. We demonstrate that high annualized relapse rate, particularly on-treatment relapse, is an indicator of poor prognosis.]]> Sat 24 Mar 2018 07:11:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49703 Mon 29 May 2023 13:00:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48108 Mon 27 Feb 2023 15:18:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36719 Mon 24 Aug 2020 10:45:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41847 p = 0.010); but no differences in spontaneous abortions, term or preterm births. Conclusions: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.]]> Mon 15 Aug 2022 10:27:59 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46218 Mon 14 Nov 2022 12:12:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54178 Mon 12 Feb 2024 13:11:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25306 Mon 06 Mar 2023 17:55:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41309 Mon 01 Aug 2022 12:30:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51882 Fri 22 Sep 2023 09:08:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41083 Fri 22 Jul 2022 17:11:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53317 Fri 19 Jan 2024 14:25:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51076 Fri 18 Aug 2023 09:03:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34026 80%) for relapse incidence during the first year and for disability outcomes, moderate for relapse incidence in Years 2–4 and for the change in the cumulative disease burden, and low for conversion to secondary progressive disease and treatment discontinuation. External validation showed similar results, demonstrating high external validity for disability and relapse outcomes, moderate external validity for cumulative disease burden and low external validity for conversion to secondary progressive disease and treatment discontinuation. We conclude that demographic, clinical and paraclinical information helps predict individual response to disease-modifying therapies at the time of their commencement.]]> Fri 01 Feb 2019 10:45:46 AEDT ]]>